epithelial cells from cellular damage by inhibiting increases in epithelial permeability caused by gliadin. 21, 22 In addition to the supplemental role that Bifidobacterial species may exert in CD, several studies have also focused on the potential role that it plays in the development of CD later in infancy. Breast milk has been shown to stimulate the growth of Bifidobacterial species in the guts of healthy newborns. In 1 prospective study on 164 healthy infants who have at least 1 first-degree relative with CD, reduced numbers of Bifidobacterium were found in infants who later had an increased risk for developing CD. [23] [24] [25] In this issue of the Journal of Clinical Gastroenterology, Smeucol et al 26 presented their results from the first clinical trial evaluating the effect of B. infantis in active, untreated CD patients still consuming gluten-containing products. The study was a placebo-controlled, doubleblinded, randomized study comparing B. infantis NSL super strain with placebo capsules. A total of 22 patients with positive tissue transglutaminase (tTG) and deamidated gliadin-derived peptides (DGP) were included in this study. Biopsies at the end of the study confirmed CD in all 22 patients. The primary endpoint of the study was to determine the effect of administration of B. infantis on intestinal permeability using the lactulose/mannitol fractional excretion ratio at the end of 3 weeks of treatment. Secondary endpoints evaluated included clinical symptom outcomes as measured by the GSRS questionnaire and whether B. infantis modified any immunologic and inflammatory markers related to CD.
This study did not meet its primary endpoint. There was no statistically significant difference in intestinal permeability between the B. infantis arm and the placebocontrolled arm at the end of the study. Potentially this was not the best primary endpoint to choose for the study, for there is controversy surrounding the use of 5-hour urine collections (as used in this study) as the assessment parameter for small intestinal permeability. 27, 28 Urine collection for the first 2 hours reflects small bowel permeability changes, whereas longer duration collections reflect colonic permeability changes. Serum antibody (tTG and DGP) levels were also collected in these patients both at the beginning and at the end of the 3-week trial on probiotics. In the probiotic arm there was a 10% reduction in serum anti-tTG IgA and IgA DGP as compared with a mean increase in the placebo arm; however, these differences did not reach statistical significance. In addition, when looking at proinflammatory cytokines and chemokines, the baseline proinflammatory status persisted in both groups of patients. Finally, this study found that, after 3 weeks of treatment with B. Infantis, patients reported improvements in indigestion, constipation, and gastroesophageal reflux as evaluated by the GSRS scale, but not improvements in diarrhea and abdominal pain.
In summary, this is an interesting study that shows a potential for the further study of the use of B. infantis probiotic therapy in untreated CD patients. Although the study is limited by its small sample size and variables such as length of treatment duration and dose of probiotic therapy, the treatment arm of the study showed an improvement in symptoms and serum antibody levels (although not statistically significant). Future studies would benefit from enrolling a larger number of patients to further delineate potential benefits of B. infantis probiotic therapy as well as from using different doses of probiotic therapy to determine whether an increased benefit is seen with increased doses. Nevertheless, this study provides encouraging and exciting uses of probiotic therapy in a yet unchartered group of patients.
However, before recommending any pharmaceutical therapy for patients with CD, the therapy must be safe and extremely effective, for the gluten-free diet is both. Any therapy needs to protect the CD patient from extremely small amounts of gluten. Although 1 slice of bread contains
